Shares of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) traded down 5.4% during trading on Wednesday . The stock traded as low as $12.45 and last traded at $12.50, with a volume of 205,590 shares. The stock had previously closed at $13.21.

Several analysts have commented on the stock. Cantor Fitzgerald restated a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Paratek Pharmaceuticals in a report on Friday, June 17th. Ladenburg Thalmann raised their target price on shares of Paratek Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, June 17th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Robert W. Baird restated an “outperform” rating and set a $40.00 target price (up from $30.00) on shares of Paratek Pharmaceuticals in a report on Friday, June 17th. Finally, HC Wainwright raised their target price on shares of Paratek Pharmaceuticals from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $35.88.

The firm’s market cap is $281.03 million. The stock’s 50 day moving average price is $13.17 and its 200-day moving average price is $14.47.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.03.

In related news, CEO Michael Bigham bought 20,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Thursday, June 23rd. The shares were acquired at an average cost of $13.45 per share, for a total transaction of $269,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 100,000 shares of the company’s stock, valued at approximately $1,345,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Fund Iv L.P. Omega bought 461,538 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, June 27th. The stock was bought at an average price of $13.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.